Minomic International is committed to developing and commercialising biomarkers for diagnosis and treatment of major diseases.
As such, Minomic International will continue to seek opportunities to work with developers and the industry as a whole.
Prostate Cancer Antibody for Imaging and Therapy Applications
In the cancer area we plan to develop the prostate cancer antibody as a therapeutic for treatment and imaging of cancer. We have shown that the antibody has excellent properties for imaging and for targeting tumours in vivo with radioactivity or a toxic moiety.
Tumour-specific or prostate tissue-specific monoclonal antibodies can be radiolabeled for immunodetection or imaging of cancer, or conjugated with toxins, drugs or radionuclides for immunotherapy. Because the antibody, and thus the molecules it can carry are selectively concentrated in tumour tissue, this modality can deliver substantial doses of a killing agent to the cancers whilst minimizing exposure of normal tissue.
For more information on upcoming diagnostics that Minomic International will be managing the commercialisation of, please contact info@minomic.com |
